{"prompt": "['does not resolve to Grade 1 within 30', 'MYASTHENIA GRAVIS:', 'days or if there are signs of respiratory', 'Steroids may be successfully used to treat myasthenia', 'insufficiency or autonomic instability.', 'gravis. They should typically be administered in a', 'monitored setting under supervision of a neurologist.', 'For Grade 4:', 'Patients unable to tolerate steroids may be candidates for', 'Permanently discontinue study', 'treatment with plasmapheresis or IV IG.', 'drug/study regimen.', 'If myasthenia gravis-like neurotoxicity present, consider', 'starting AChE inhibitor therapy in addition to steroids.', 'Such therapy, if successful, can also serve to reinforce the', 'diagnosis.', 'GUILLAIN-BARRE:', 'It is important to consider here that the use of steroids as', 'the primary treatment of Guillain-Barre is not typically', 'considered effective.', 'Patients requiring treatment should be started with IV IG', 'and followed by plasmapheresis if not responsive to IV', 'IG.', 'Others imAEs', 'Myositis/Polymyositis', 'Management', 'Follow-up', '(\"Poly/myositis\")', 'Grade 1 (mild pain)', 'No dose modifications.', 'Monitor and closely follow up in 2 to 4 days for clinical', 'symptoms and initiate evaluation as clinically indicated.', 'Consider neurology consult.', 'Consider, as necessary, discussing with the study', 'physician.', 'Grade 2', 'Hold study drug/study regimen dose', 'Monitor symptoms daily and consider hospitalization.', '(moderate pain associated', 'until resolution to Grade <1.', 'Obtain Neurology consult, and initiate evaluation.', 'with weakness; pain', 'Permanently discontinue study', 'Consider, as necessary, discussing with the study', 'limiting instrumental', 'drug/study regimen if it does not resolve', 'physician.', 'activities of daily living', 'to Grade 1 within 30 days or if there', '[ADLs])', 'are signs of respiratory insufficiency.', 'If clinical course is rapidly progressive (particularly if', 'difficulty breathing and/or trouble swallowing), promptly', 'start IV methylprednisolone 2 to 4 mg/kg/day systemic', 'steroids along with receiving input from neurology', 'consultant', 'If clinical course is not rapidly progressive, start systemic', 'steroids (e.g., prednisone 1 to 2 mg/kg/day PO or IV', 'equivalent); if no improvement within 3 to 5 days,', 'continue additional work up and start treatment with IV', 'methylprednisolone 2 to 4 mg/kg/day.', 'If after start of IV methylprednisolone at 2 to 4 mg/kg/day', 'there is no improvement within 3 to 5 days, consider start', 'of immunosuppressive therapy such as TNF inhibitors', '(e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is', 'important to rule out sepsis and refer to infliximab label', 'for general guidance before using infliximab.', 'Once the patient is improving, gradually taper steroids', 'over >28 days and consider prophylactic antibiotics,', 'antifungals, or anti-Pneumocystis jirovecii pneumonia', 'treatment (refer to current NCCN guidelines for treatment', 'of cancer-related infections [Category 2B', 'recommendation].', 'Grade 3 or 4', 'For Grade 3:', 'Monitor symptoms closely; recommend hospitalization.', '(pain associated with', 'Hold study drug/study regimen dose', 'Obtain neurology consult, and complete full evaluation.', 'severe weakness; limiting', 'until resolution to Grade 1.', 'Consider, as necessary, discussing with the study', 'self-care ADLs)', 'Permanently discontinue study', 'physician.', 'drug/study regimen if Grade 3 imAE', 'Promptly start IV methylprednisolone 2 to 4 mg/kg/day', 'does not resolve to Grade 1 within 30', 'systemic steroids along with receiving input from', 'days or if there are signs of respiratory', 'neurology consultant.', 'insufficiency.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 34 de 123']['If after start of IV methylprednisolone at 2 to 4 mg/kg/day', 'For Grade 4:', 'there is no improvement within 3 to 5 days, consider start', 'of immunosuppressive therapy such as TNF inhibitors', 'Permanently discontinue study', '(e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It is', 'drug/study regimen.', 'important to rule out sepsis and refer to infliximab label', 'for general guidance before using infliximab.', 'Consider whether patient may require IV IG,', 'plasmapheresis.', 'Once the patient is improving, gradually taper steroids', 'over >28 days and consider prophylactic antibiotics,', 'antifungals, or anti-Pneumocystis jirovecii pneumonia', 'treatment (refer to current NCCN guidelines for treatment', 'of cancer-related infections [Category 2B', 'recommendation]).', 'asco Educational Book 2015 \"Managing Immune Checkpoint Blocking Antibody Side Effects\" by Michael Postow MD.', '7.6. Partial treatments stop', 'The treatment regimen must include at the beginning FOLFIRI plus durvalumab +/- tremelimumab,', 'depending on treatment arm, but if severe toxicities occur some drugs can be stopped while the other drugs', 'continued.', 'Regimen allowed', '5-FU/LV', 'Irinotecan', 'Durvalumab', 'Tremelimumab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Regimen not allowed', '5-FU/LV', 'Irinotecan', 'Durvalumab', 'Tremelimumab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Main toxicities that will induce a partial treatment stop are:', '- Immune-mediated adverse event grade 3-4 may need durvalumab +/- tremelimumab stop: FOLFIRI can be', 'continued alone.', '- Severe digestive toxicities due to chemotherapy may need irinotecan +/- 5FU stop: 5FU plus durvalumab +/-', 'tremelimumab can be continued or durvalumab (with or without tremelimumab) alone.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 35 de 123']\n\n###\n\n", "completion": "END"}